Literature DB >> 35599283

Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms.

Maira da Costa Cacemiro1, Juçara Gastaldi Cominal2, Luiz Miguel Pereira2, Maria Gabriela Berzoti-Coelho2, Giovana Michelassi Berbel2, Luciana Baroni2, Tathiane Malta2, Raquel Tognon3, Natalia de Souza Nunes2, Elizabeth Xisto Souto4, Lorena Lobo de Figueiredo-Pontes5, Ana Patricia Yatsuda2, Fabíola Attié de Castro6.   

Abstract

Myeloproliferative neoplasms (MPN) are hematological disorders characterized by increased proliferation of precursor and mature myeloid cells. MPN patients may present driver mutations in JAK2, MPL, and CALR genes, which are essential to describe the molecular mechanisms of MPN pathogenesis. Despite all the new knowledge on MPN pathogenesis, many questions remain to be answered to develop effective therapies to cure MPN or impair its progression to acute myeloid leukemia. The present study examined the expression levels of the Hippo signaling pathway members in patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), as well as the role that they play in disease pathogenesis. The Hippo pathway is a tumor suppressor pathway that participates in the regulation of cell proliferation, differentiation, and death. Our main finding was that the expression of tumor suppressor genes from Hippo pathway were downregulated and seemed to be associated with cell resistance to apoptosis and increased proliferation rate. Therefore, the decreased expression of Hippo pathway-related genes may contribute to the malignant phenotype, apoptosis resistance, and cell proliferation in MPN pathogenesis.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Apoptosis; Cell proliferation; Hippo signaling pathway; LATS2; Myeloproliferative neoplasms

Mesh:

Substances:

Year:  2022        PMID: 35599283     DOI: 10.1007/s12032-022-01696-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  40 in total

1.  Some speculations on the myeloproliferative syndromes.

Authors:  W DAMESHEK
Journal:  Blood       Date:  1951-04       Impact factor: 22.113

2.  Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide.

Authors:  Cornelis J J Huijsmans; Jeroen Poodt; Paul H M Savelkoul; Mirjam H A Hermans
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

3.  Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages.

Authors:  T Kodama; H Hikita; T Kawaguchi; M Shigekawa; S Shimizu; Y Hayashi; W Li; T Miyagi; A Hosui; T Tatsumi; T Kanto; N Hiramatsu; K Kiyomizu; S Tadokoro; Y Tomiyama; N Hayashi; T Takehara
Journal:  Cell Death Differ       Date:  2012-07-13       Impact factor: 15.828

Review 4.  Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

Authors:  Ruben A Mesa; Srdan Verstovsek; Francisco Cervantes; Giovanni Barosi; John T Reilly; Brigitte Dupriez; Ross Levine; Marie-Caroline Le Bousse-Kerdiles; Martha Wadleigh; Peter J Campbell; Richard T Silver; Alessandro M Vannucchi; H Joachim Deeg; Heinz Gisslinger; Deborah Thomas; Olatoyosi Odenike; Lawrence A Solberg; Jason Gotlib; Elizabeth Hexner; Stephen D Nimer; Hagop Kantarjian; Attilio Orazi; James W Vardiman; Juergen Thiele; Ayalew Tefferi
Journal:  Leuk Res       Date:  2007-01-08       Impact factor: 3.156

5.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

6.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

7.  MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Authors:  Animesh D Pardanani; Ross L Levine; Terra Lasho; Yana Pikman; Ruben A Mesa; Martha Wadleigh; David P Steensma; Michelle A Elliott; Alexandra P Wolanskyj; William J Hogan; Rebecca F McClure; Mark R Litzow; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2006-07-25       Impact factor: 22.113

8.  New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.

Authors:  R Chaligné; C Tonetti; R Besancenot; L Roy; C Marty; P Mossuz; J-J Kiladjian; G Socié; D Bordessoule; M-C Le Bousse-Kerdilès; W Vainchenker; S Giraudier
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

9.  Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis.

Authors:  Raquel Tognon; Elainy P L Gasparotto; Renata P Neves; Natália S Nunes; Aline F Ferreira; Patrícia V B Palma; Simone Kashima; Dimas T Covas; Mary Santana; Elizabeth X Souto; Maria Aparecida Zanichelli; Belinda P Simões; Ana Maria de Souza; Fabíola A Castro
Journal:  J Hematol Oncol       Date:  2012-02-02       Impact factor: 17.388

Review 10.  Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.

Authors:  Marito Araki; Norio Komatsu
Journal:  Cancer Sci       Date:  2017-08-08       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.